https://www.selleckchem.com/products/mek162.html
hould be used to define initial deficits, guide therapeutic decisions, and document treatment response. ANN NEUROL 2021;89753-768. Patients with autoimmune autonomic ganglionopathy demonstrated objective evidence of widespread sympathetic and parasympathetic autonomic failure, with significant improvements after immunotherapy. Quantitative autonomic biomarkers should be used to define initial deficits, guide therapeutic decisions, and document treatment response. ANN NEUROL 2021;89753-768.This study investigated the effects of non-phosph
Like
Comment
Share
